Impact of early detection on cancer curability: A modified Delphi panel study
Name:
journal.pone.0279227.pdf
Size:
747.5Kb
Format:
PDF
Description:
Final Published Version
Author
Schwartzberg, L.Broder, M.S.
Ailawadhi, S.
Beltran, H.
Blakely, L.J.
Budd, G.T.
Carr, L.
Cecchini, M.
Cobb, P.
Kansal, A.
Kim, A.
Monk, B.J.
Wong, D.J.
Campos, C.
Yermilov, I.
Affiliation
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, HonorHealth Research Institute, University of ArizonaIssue Date
2022-12-21
Metadata
Show full item recordPublisher
Public Library of ScienceCitation
Schwartzberg, L., Broder, M. S., Ailawadhi, S., Beltran, H., Blakely, L. J., Budd, G. T., Carr, L., Cecchini, M., Cobb, P., Kansal, A., Kim, A., Monk, B. J., Wong, D. J., Campos, C., & Yermilov, I. (2022). Impact of early detection on cancer curability: A modified Delphi panel study. PLoS ONE, 17(12 December).Journal
PLoS ONERights
© 2022 Schwartzberg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Expert consensus on the potential benefits of early cancer detection does not exist for most cancer types. We convened 10 practicing oncologists using a RAND/UCLA modified Delphi panel to evaluate which of 20 solid tumors, representing >40 American Joint Committee on Cancer (AJCC)-identified cancer types and 80% of total cancer incidence, would receive potential clinical benefits from early detection. Pre-meeting, experts estimated how long cancers take to progress and rated the current curability and benefit (improvement in curability) of an annual hypothetical multi-cancer screening blood test. Post-meeting, experts rerated all questions. Cancers had varying estimates of the potential benefit of early cancer detection depending on estimates of their curability and progression by stage. Cancers rated as progressing quickly and being curable in earlier stages (stomach, esophagus, lung, urothelial tract, melanoma, ovary, sarcoma, bladder, cervix, breast, colon/rectum, kidney, uterus, anus, head and neck) were estimated to be most likely to benefit from a hypothetical screening blood test. Cancer types rated as progressing quickly but having comparatively lower cure rates in earlier stages (liver/intrahepatic bile duct, gallbladder, pancreas) were estimated to have medium likelihood of benefit from a hypothetical screening blood test. Cancer types rated as progressing more slowly and having higher curability regardless of stage (prostate, thyroid) were estimated to have limited likelihood of benefit from a hypothetical screening blood test. The panel concluded most solid tumors have a likelihood of benefit from early detection. Even among difficult-to-treat cancers (e.g., pancreas, liver/ intrahepatic bile duct, gallbladder), early-stage detection was believed to be beneficial. Based on the panel consensus, broad coverage of cancers by screening blood tests would deliver the greatest potential benefits to patients. © 2022 Schwartzberg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Note
Open access journalISSN
1932-6203PubMed ID
36542647Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0279227
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2022 Schwartzberg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Related articles
- Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
- Authors: AIRTUM Working Group, Busco S, Buzzoni C, Mallone S, Trama A, Castaing M, Bella F, Amodio R, Bizzoco S, Cassetti T, Cirilli C, Cusimano R, De Angelis R, Fusco M, Gatta G, Gennaro V, Giacomin A, Giorgi Rossi P, Mangone L, Mannino S, Rossi S, Pierannunzio D, Tavilla A, Tognazzo S, Tumino R, Vicentini M, Vitale MF, Crocetti E, Dal Maso L
- Issue date: 2016 Jan-Feb
- Solid cancer incidence in atomic bomb survivors: 1958-1998.
- Authors: Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K
- Issue date: 2007 Jul
- Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
- Authors: Lew JB, Feletto E, Wade S, Caruana M, Kang YJ, Nickson C, Simms KT, Procopio P, Taylor N, Worthington J, Smith D, Canfell K
- Issue date: 2019 Jul 31
- Annual report to the nation on the status of cancer, part 1: National cancer statistics.
- Authors: Cronin KA, Scott S, Firth AU, Sung H, Henley SJ, Sherman RL, Siegel RL, Anderson RN, Kohler BA, Benard VB, Negoita S, Wiggins C, Cance WG, Jemal A
- Issue date: 2022 Dec 15
- Mammography screening: A major issue in medicine.
- Authors: Autier P, Boniol M
- Issue date: 2018 Feb